Summary
Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product's patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.
According to APO Research, The global Biosimilar Insulin market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Biosimilar Insulin is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Biosimilar Insulin is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Biosimilar Insulin is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Biosimilar Insulin is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global manufacturers of Biosimilar Insulin include Eli Lilly, Sanofi, Gan&Lee, Tonghua Dongbao, United Laboratory, Geropharm, Biocon and Wockhardt, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Biosimilar Insulin, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Biosimilar Insulin, also provides the sales of main regions and countries. Of the upcoming market potential for Biosimilar Insulin, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Biosimilar Insulin sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Biosimilar Insulin market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Biosimilar Insulin sales, projected growth trends, production technology, application and end-user industry.
Biosimilar Insulin segment by Company
Eli Lilly
Sanofi
Gan&Lee
Tonghua Dongbao
United Laboratory
Geropharm
Biocon
Wockhardt
Biosimilar Insulin segment by Type
Biosimilar Insulin Glargine
Biosimilar Insulin Lispro
Other
Biosimilar Insulin segment by Distribution Channel
Hospital
Retail Pharmacy
Others
Biosimilar Insulin segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Insulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilar Insulin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Insulin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Biosimilar Insulin in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Biosimilar Insulin manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biosimilar Insulin sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
1 Market Overview
1.1 Product Definition
1.2 Biosimilar Insulin Market by Type
1.2.1 Global Biosimilar Insulin Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Biosimilar Insulin Glargine
1.2.3 Biosimilar Insulin Lispro
1.2.4 Other
1.3 Biosimilar Insulin Market by Distribution Channel
1.3.1 Global Biosimilar Insulin Market Size by Distribution Channel, 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Biosimilar Insulin Market Dynamics
2.1 Biosimilar Insulin Industry Trends
2.2 Biosimilar Insulin Industry Drivers
2.3 Biosimilar Insulin Industry Opportunities and Challenges
2.4 Biosimilar Insulin Industry Restraints
3 Global Market Growth Prospects
3.1 Global Biosimilar Insulin Revenue Estimates and Forecasts (2019-2030)
3.2 Global Biosimilar Insulin Revenue by Region
3.2.1 Global Biosimilar Insulin Revenue by Region: 2019 VS 2023 VS 2030
3.2.2 Global Biosimilar Insulin Revenue by Region (2019-2024)
3.2.3 Global Biosimilar Insulin Revenue by Region (2025-2030)
3.2.4 Global Biosimilar Insulin Revenue Market Share by Region (2019-2030)
3.3 Global Biosimilar Insulin Sales Estimates and Forecasts 2019-2030
3.4 Global Biosimilar Insulin Sales by Region
3.4.1 Global Biosimilar Insulin Sales by Region: 2019 VS 2023 VS 2030
3.4.2 Global Biosimilar Insulin Sales by Region (2019-2024)
3.4.3 Global Biosimilar Insulin Sales by Region (2025-2030)
3.4.4 Global Biosimilar Insulin Sales Market Share by Region (2019-2030)
3.5 US & Canada
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 Middle East, Africa and Latin America
4 Market Competitive Landscape by Manufacturers
4.1 Global Biosimilar Insulin Revenue by Manufacturers
4.1.1 Global Biosimilar Insulin Revenue by Manufacturers (2019-2024)
4.1.2 Global Biosimilar Insulin Revenue Market Share by Manufacturers (2019-2024)
4.1.3 Global Biosimilar Insulin Manufacturers Revenue Share Top 10 and Top 5 in 2023
4.2 Global Biosimilar Insulin Sales by Manufacturers
4.2.1 Global Biosimilar Insulin Sales by Manufacturers (2019-2024)
4.2.2 Global Biosimilar Insulin Sales Market Share by Manufacturers (2019-2024)
4.2.3 Global Biosimilar Insulin Manufacturers Sales Share Top 10 and Top 5 in 2023
4.3 Global Biosimilar Insulin Sales Price by Manufacturers (2019-2024)
4.4 Global Biosimilar Insulin Key Manufacturers Ranking, 2022 VS 2023 VS 2024
4.5 Global Biosimilar Insulin Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global Biosimilar Insulin Manufacturers, Product Type & Application
4.7 Global Biosimilar Insulin Manufacturers Commercialization Time
4.8 Market Competitive Analysis
4.8.1 Global Biosimilar Insulin Market CR5 and HHI
4.8.2 2023 Biosimilar Insulin Tier 1, Tier 2, and Tier 3
5 Biosimilar Insulin Market by Type
5.1 Global Biosimilar Insulin Revenue by Type
5.1.1 Global Biosimilar Insulin Revenue by Type (2019 VS 2023 VS 2030)
5.1.2 Global Biosimilar Insulin Revenue by Type (2019-2030) & (US$ Million)
5.1.3 Global Biosimilar Insulin Revenue Market Share by Type (2019-2030)
5.2 Global Biosimilar Insulin Sales by Type
5.2.1 Global Biosimilar Insulin Sales by Type (2019 VS 2023 VS 2030)
5.2.2 Global Biosimilar Insulin Sales by Type (2019-2030) & (K Unit)
5.2.3 Global Biosimilar Insulin Sales Market Share by Type (2019-2030)
5.3 Global Biosimilar Insulin Price by Type
6 Biosimilar Insulin Market by Application
6.1 Global Biosimilar Insulin Revenue by Application
6.1.1 Global Biosimilar Insulin Revenue by Application (2019 VS 2023 VS 2030)
6.1.2 Global Biosimilar Insulin Revenue by Application (2019-2030) & (US$ Million)
6.1.3 Global Biosimilar Insulin Revenue Market Share by Application (2019-2030)
6.2 Global Biosimilar Insulin Sales by Application
6.2.1 Global Biosimilar Insulin Sales by Application (2019 VS 2023 VS 2030)
6.2.2 Global Biosimilar Insulin Sales by Application (2019-2030) & (K Unit)
6.2.3 Global Biosimilar Insulin Sales Market Share by Application (2019-2030)
6.3 Global Biosimilar Insulin Price by Application
7 Company Profiles
7.1 Eli Lilly
7.1.1 Eli Lilly Comapny Information
7.1.2 Eli Lilly Business Overview
7.1.3 Eli Lilly Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2019-2024)
7.1.4 Eli Lilly Biosimilar Insulin Product Portfolio
7.1.5 Eli Lilly Recent Developments
7.2 Sanofi
7.2.1 Sanofi Comapny Information
7.2.2 Sanofi Business Overview
7.2.3 Sanofi Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2019-2024)
7.2.4 Sanofi Biosimilar Insulin Product Portfolio
7.2.5 Sanofi Recent Developments
7.3 Gan&Lee
7.3.1 Gan&Lee Comapny Information
7.3.2 Gan&Lee Business Overview
7.3.3 Gan&Lee Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2019-2024)
7.3.4 Gan&Lee Biosimilar Insulin Product Portfolio
7.3.5 Gan&Lee Recent Developments
7.4 Tonghua Dongbao
7.4.1 Tonghua Dongbao Comapny Information
7.4.2 Tonghua Dongbao Business Overview
7.4.3 Tonghua Dongbao Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2019-2024)
7.4.4 Tonghua Dongbao Biosimilar Insulin Product Portfolio
7.4.5 Tonghua Dongbao Recent Developments
7.5 United Laboratory
7.5.1 United Laboratory Comapny Information
7.5.2 United Laboratory Business Overview
7.5.3 United Laboratory Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2019-2024)
7.5.4 United Laboratory Biosimilar Insulin Product Portfolio
7.5.5 United Laboratory Recent Developments
7.6 Geropharm
7.6.1 Geropharm Comapny Information
7.6.2 Geropharm Business Overview
7.6.3 Geropharm Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2019-2024)
7.6.4 Geropharm Biosimilar Insulin Product Portfolio
7.6.5 Geropharm Recent Developments
7.7 Biocon
7.7.1 Biocon Comapny Information
7.7.2 Biocon Business Overview
7.7.3 Biocon Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2019-2024)
7.7.4 Biocon Biosimilar Insulin Product Portfolio
7.7.5 Biocon Recent Developments
7.8 Wockhardt
7.8.1 Wockhardt Comapny Information
7.8.2 Wockhardt Business Overview
7.8.3 Wockhardt Biosimilar Insulin Sales, Revenue, Price and Gross Margin (2019-2024)
7.8.4 Wockhardt Biosimilar Insulin Product Portfolio
7.8.5 Wockhardt Recent Developments
8 North America
8.1 North America Biosimilar Insulin Market Size by Type
8.1.1 North America Biosimilar Insulin Revenue by Type (2019-2030)
8.1.2 North America Biosimilar Insulin Sales by Type (2019-2030)
8.1.3 North America Biosimilar Insulin Price by Type (2019-2030)
8.2 North America Biosimilar Insulin Market Size by Distribution Channel
8.2.1 North America Biosimilar Insulin Revenue by Distribution Channel (2019-2030)
8.2.2 North America Biosimilar Insulin Sales by Distribution Channel (2019-2030)
8.2.3 North America Biosimilar Insulin Price by Distribution Channel (2019-2030)
8.3 North America Biosimilar Insulin Market Size by Country
8.3.1 North America Biosimilar Insulin Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
8.3.2 North America Biosimilar Insulin Sales by Country (2019 VS 2023 VS 2030)
8.3.3 North America Biosimilar Insulin Price by Country (2019-2030)
8.3.4 United States
8.3.5 Canada
9 Europe
9.1 Europe Biosimilar Insulin Market Size by Type
9.1.1 Europe Biosimilar Insulin Revenue by Type (2019-2030)
9.1.2 Europe Biosimilar Insulin Sales by Type (2019-2030)
9.1.3 Europe Biosimilar Insulin Price by Type (2019-2030)
9.2 Europe Biosimilar Insulin Market Size by Distribution Channel
9.2.1 Europe Biosimilar Insulin Revenue by Distribution Channel (2019-2030)
9.2.2 Europe Biosimilar Insulin Sales by Distribution Channel (2019-2030)
9.2.3 Europe Biosimilar Insulin Price by Distribution Channel (2019-2030)
9.3 Europe Biosimilar Insulin Market Size by Country
9.3.1 Europe Biosimilar Insulin Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
9.3.2 Europe Biosimilar Insulin Sales by Country (2019 VS 2023 VS 2030)
9.3.3 Europe Biosimilar Insulin Price by Country (2019-2030)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Russia
10 China
10.1 China Biosimilar Insulin Market Size by Type
10.1.1 China Biosimilar Insulin Revenue by Type (2019-2030)
10.1.2 China Biosimilar Insulin Sales by Type (2019-2030)
10.1.3 China Biosimilar Insulin Price by Type (2019-2030)
10.2 China Biosimilar Insulin Market Size by Distribution Channel
10.2.1 China Biosimilar Insulin Revenue by Distribution Channel (2019-2030)
10.2.2 China Biosimilar Insulin Sales by Distribution Channel (2019-2030)
10.2.3 China Biosimilar Insulin Price by Distribution Channel (2019-2030)
11 Asia (Excluding China)
11.1 Asia Biosimilar Insulin Market Size by Type
11.1.1 Asia Biosimilar Insulin Revenue by Type (2019-2030)
11.1.2 Asia Biosimilar Insulin Sales by Type (2019-2030)
11.1.3 Asia Biosimilar Insulin Price by Type (2019-2030)
11.2 Asia Biosimilar Insulin Market Size by Distribution Channel
11.2.1 Asia Biosimilar Insulin Revenue by Distribution Channel (2019-2030)
11.2.2 Asia Biosimilar Insulin Sales by Distribution Channel (2019-2030)
11.2.3 Asia Biosimilar Insulin Price by Distribution Channel (2019-2030)
11.3 Asia Biosimilar Insulin Market Size by Country
11.3.1 Asia Biosimilar Insulin Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
11.3.2 Asia Biosimilar Insulin Sales by Country (2019 VS 2023 VS 2030)
11.3.3 Asia Biosimilar Insulin Price by Country (2019-2030)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 China Taiwan
11.3.9 Southeast Asia
12 Middle East, Africa and Latin America
12.1 MEALA Biosimilar Insulin Market Size by Type
12.1.1 MEALA Biosimilar Insulin Revenue by Type (2019-2030)
12.1.2 MEALA Biosimilar Insulin Sales by Type (2019-2030)
12.1.3 MEALA Biosimilar Insulin Price by Type (2019-2030)
12.2 MEALA Biosimilar Insulin Market Size by Distribution Channel
12.2.1 MEALA Biosimilar Insulin Revenue by Distribution Channel (2019-2030)
12.2.2 MEALA Biosimilar Insulin Sales by Distribution Channel (2019-2030)
12.2.3 MEALA Biosimilar Insulin Price by Distribution Channel (2019-2030)
12.3 MEALA Biosimilar Insulin Market Size by Country
12.3.1 MEALA Biosimilar Insulin Revenue Grow Rate by Country (2019 VS 2023 VS 2030)
12.3.2 MEALA Biosimilar Insulin Sales by Country (2019 VS 2023 VS 2030)
12.3.3 MEALA Biosimilar Insulin Price by Country (2019-2030)
12.3.4 Mexico
12.3.5 Brazil
12.3.6 Israel
12.3.7 Argentina
12.3.8 Colombia
12.3.9 Turkey
12.3.10 Saudi Arabia
12.3.11 UAE
13 Value Chain and Sales Channels Analysis
13.1 Biosimilar Insulin Value Chain Analysis
13.1.1 Biosimilar Insulin Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 Biosimilar Insulin Production Mode & Process
13.2 Biosimilar Insulin Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 Biosimilar Insulin Distributors
13.2.3 Biosimilar Insulin Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
List of Tables
Table 1. Global Biosimilar Insulin Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 2. Biosimilar Insulin Glargine Major Manufacturers
Table 3. Biosimilar Insulin Lispro Major Manufacturers
Table 4. Other Major Manufacturers
Table 5. Global Biosimilar Insulin Market Size Growth Rate by Distribution Channel (US$ Million), 2019 VS 2023 VS 2030
Table 6. Hospital Major Manufacturers
Table 7. Retail Pharmacy Major Manufacturers
Table 8. Others Major Manufacturers
Table 9. Biosimilar Insulin Industry Trends
Table 10. Biosimilar Insulin Industry Drivers
Table 11. Biosimilar Insulin Industry Opportunities and Challenges
Table 12. Biosimilar Insulin Industry Restraints
Table 13. Global Biosimilar Insulin Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Biosimilar Insulin Revenue by Region (2019-2024) & (US$ Million)
Table 15. Global Biosimilar Insulin Revenue by Region (2025-2030) & (US$ Million)
Table 16. Global Biosimilar Insulin Revenue Market Share by Region (2019-2024)
Table 17. Global Biosimilar Insulin Revenue Market Share by Region (2025-2030)
Table 18. Global Biosimilar Insulin Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (K Unit)
Table 19. Global Biosimilar Insulin Sales by Region (2019-2024) & (K Unit)
Table 20. Global Biosimilar Insulin Sales by Region (2025-2030) & (K Unit)
Table 21. Global Biosimilar Insulin Sales Market Share by Region (2019-2024)
Table 22. Global Biosimilar Insulin Sales Market Share by Region (2025-2030)
Table 23. Global Biosimilar Insulin Revenue by Manufacturers (US$ Million) & (2019-2024)
Table 24. Global Biosimilar Insulin Revenue Market Share by Manufacturers (2019-2024)
Table 25. Global Biosimilar Insulin Sales by Manufacturers (US$ Million) & (2019-2024)
Table 26. Global Biosimilar Insulin Sales Market Share by Manufacturers (2019-2024)
Table 27. Global Biosimilar Insulin Sales Price (US$/Unit) of Manufacturers (2019-2024)
Table 28. Global Biosimilar Insulin Key Manufacturers Ranking, 2022 VS 2023 VS 2024
Table 29. Global Biosimilar Insulin Key Manufacturers Manufacturing Sites & Headquarters
Table 30. Global Biosimilar Insulin Manufacturers, Product Type & Application
Table 31. Global Biosimilar Insulin Manufacturers Commercialization Time
Table 32. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 33. Global Biosimilar Insulin by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 34. Global Biosimilar Insulin Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 35. Global Biosimilar Insulin Revenue by Type (2019-2024) & (US$ Million)
Table 36. Global Biosimilar Insulin Revenue by Type (2025-2030) & (US$ Million)
Table 37. Global Biosimilar Insulin Revenue Market Share by Type (2019-2024)
Table 38. Global Biosimilar Insulin Revenue Market Share by Type (2025-2030)
Table 39. Global Biosimilar Insulin Sales by Type 2019 VS 2023 VS 2030 (K Unit)
Table 40. Global Biosimilar Insulin Sales by Type (2019-2024) & (K Unit)
Table 41. Global Biosimilar Insulin Sales by Type (2025-2030) & (K Unit)
Table 42. Global Biosimilar Insulin Sales Market Share by Type (2019-2024)
Table 43. Global Biosimilar Insulin Sales Market Share by Type (2025-2030)
Table 44. Global Biosimilar Insulin Price by Type (2019-2024) & (US$/Unit)
Table 45. Global Biosimilar Insulin Price by Type (2025-2030) & (US$/Unit)
Table 46. Global Biosimilar Insulin Revenue by Distribution Channel 2019 VS 2023 VS 2030 (US$ Million)
Table 47. Global Biosimilar Insulin Revenue by Distribution Channel (2019-2024) & (US$ Million)
Table 48. Global Biosimilar Insulin Revenue by Distribution Channel (2025-2030) & (US$ Million)
Table 49. Global Biosimilar Insulin Revenue Market Share by Distribution Channel (2019-2024)
Table 50. Global Biosimilar Insulin Revenue Market Share by Distribution Channel (2025-2030)
Table 51. Global Biosimilar Insulin Sales by Distribution Channel 2019 VS 2023 VS 2030 (K Unit)
Table 52. Global Biosimilar Insulin Sales by Distribution Channel (2019-2024) & (K Unit)
Table 53. Global Biosimilar Insulin Sales by Distribution Channel (2025-2030) & (K Unit)
Table 54. Global Biosimilar Insulin Sales Market Share by Distribution Channel (2019-2024)
Table 55. Global Biosimilar Insulin Sales Market Share by Distribution Channel (2025-2030)
Table 56. Global Biosimilar Insulin Price by Distribution Channel (2019-2024) & (US$/Unit)
Table 57. Global Biosimilar Insulin Price by Distribution Channel (2025-2030) & (US$/Unit)
Table 58. Eli Lilly Company Information
Table 59. Eli Lilly Business Overview
Table 60. Eli Lilly Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 61. Eli Lilly Biosimilar Insulin Product Portfolio
Table 62. Eli Lilly Recent Development
Table 63. Sanofi Company Information
Table 64. Sanofi Business Overview
Table 65. Sanofi Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 66. Sanofi Biosimilar Insulin Product Portfolio
Table 67. Sanofi Recent Development
Table 68. Gan&Lee Company Information
Table 69. Gan&Lee Business Overview
Table 70. Gan&Lee Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 71. Gan&Lee Biosimilar Insulin Product Portfolio
Table 72. Gan&Lee Recent Development
Table 73. Tonghua Dongbao Company Information
Table 74. Tonghua Dongbao Business Overview
Table 75. Tonghua Dongbao Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 76. Tonghua Dongbao Biosimilar Insulin Product Portfolio
Table 77. Tonghua Dongbao Recent Development
Table 78. United Laboratory Company Information
Table 79. United Laboratory Business Overview
Table 80. United Laboratory Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 81. United Laboratory Biosimilar Insulin Product Portfolio
Table 82. United Laboratory Recent Development
Table 83. Geropharm Company Information
Table 84. Geropharm Business Overview
Table 85. Geropharm Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 86. Geropharm Biosimilar Insulin Product Portfolio
Table 87. Geropharm Recent Development
Table 88. Biocon Company Information
Table 89. Biocon Business Overview
Table 90. Biocon Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 91. Biocon Biosimilar Insulin Product Portfolio
Table 92. Biocon Recent Development
Table 93. Wockhardt Company Information
Table 94. Wockhardt Business Overview
Table 95. Wockhardt Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 96. Wockhardt Biosimilar Insulin Product Portfolio
Table 97. Wockhardt Recent Development
Table 98. North America Biosimilar Insulin Revenue by Type (2019-2024) & (US$ Million)
Table 99. North America Biosimilar Insulin Revenue by Type (2025-2030) & (US$ Million)
Table 100. North America Biosimilar Insulin Sales by Type (2019-2024) & (K Unit)
Table 101. North America Biosimilar Insulin Sales by Type (2025-2030) & (K Unit)
Table 102. North America Biosimilar Insulin Sales Price by Type (2019-2024) & (US$/Unit)
Table 103. North America Biosimilar Insulin Sales Price by Type (2025-2030) & (US$/Unit)
Table 104. North America Biosimilar Insulin Revenue by Distribution Channel (2019-2024) & (US$ Million)
Table 105. North America Biosimilar Insulin Revenue by Distribution Channel (2025-2030) & (US$ Million)
Table 106. North America Biosimilar Insulin Sales by Distribution Channel (2019-2024) & (K Unit)
Table 107. North America Biosimilar Insulin Sales by Distribution Channel (2025-2030) & (K Unit)
Table 108. North America Biosimilar Insulin Sales Price by Distribution Channel (2019-2024) & (US$/Unit)
Table 109. North America Biosimilar Insulin Sales Price by Distribution Channel (2025-2030) & (US$/Unit)
Table 110. North America Biosimilar Insulin Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 111. North America Biosimilar Insulin Revenue Grow Rate by Country (2019-2024) & (US$ Million)
Table 112. North America Biosimilar Insulin Revenue Grow Rate by Country (2025-2030) & (US$ Million)
Table 113. North America Biosimilar Insulin Sales by Country (2019 VS 2023 VS 2030) & (K Unit)
Table 114. North America Biosimilar Insulin Sales by Country (2019-2024) & (K Unit)
Table 115. North America Biosimilar Insulin Sales by Country (2025-2030) & (K Unit)
Table 116. North America Biosimilar Insulin Sales Price by Country (2019-2024) & (US$/Unit)
Table 117. North America Biosimilar Insulin Sales Price by Country (2025-2030) & (US$/Unit)
Table 118. US Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Table 119. Canada Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Table 120. Europe Biosimilar Insulin Revenue by Type (2019-2024) & (US$ Million)
Table 121. Europe Biosimilar Insulin Revenue by Type (2025-2030) & (US$ Million)
Table 122. Europe Biosimilar Insulin Sales by Type (2019-2024) & (K Unit)
Table 123. Europe Biosimilar Insulin Sales by Type (2025-2030) & (K Unit)
Table 124. Europe Biosimilar Insulin Sales Price by Type (2019-2024) & (US$/Unit)
Table 125. Europe Biosimilar Insulin Sales Price by Type (2025-2030) & (US$/Unit)
Table 126. Europe Biosimilar Insulin Revenue by Distribution Channel (2019-2024) & (US$ Million)
Table 127. Europe Biosimilar Insulin Revenue by Distribution Channel (2025-2030) & (US$ Million)
Table 128. Europe Biosimilar Insulin Sales by Distribution Channel (2019-2024) & (K Unit)
Table 129. Europe Biosimilar Insulin Sales by Distribution Channel (2025-2030) & (K Unit)
Table 130. Europe Biosimilar Insulin Sales Price by Distribution Channel (2019-2024) & (US$/Unit)
Table 131. Europe Biosimilar Insulin Sales Price by Distribution Channel (2025-2030) & (US$/Unit)
Table 132. Europe Biosimilar Insulin Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 133. Europe Biosimilar Insulin Revenue Grow Rate by Country (2019-2024) & (US$ Million)
Table 134. Europe Biosimilar Insulin Revenue Grow Rate by Country (2025-2030) & (US$ Million)
Table 135. Europe Biosimilar Insulin Sales by Country (2019 VS 2023 VS 2030) & (K Unit)
Table 136. Europe Biosimilar Insulin Sales by Country (2019-2024) & (K Unit)
Table 137. Europe Biosimilar Insulin Sales by Country (2025-2030) & (K Unit)
Table 138. Europe Biosimilar Insulin Sales Price by Country (2019-2024) & (US$/Unit)
Table 139. Europe Biosimilar Insulin Sales Price by Country (2025-2030) & (US$/Unit)
Table 140. Germany Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Table 141. France Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Table 142. Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Table 143. Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Table 144. Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Table 145. China Biosimilar Insulin Revenue by Type (2019-2024) & (US$ Million)
Table 146. China Biosimilar Insulin Revenue by Type (2025-2030) & (US$ Million)
Table 147. China Biosimilar Insulin Sales by Type (2019-2024) & (K Unit)
Table 148. China Biosimilar Insulin Sales by Type (2025-2030) & (K Unit)
Table 149. China Biosimilar Insulin Sales Price by Type (2019-2024) & (US$/Unit)
Table 150. China Biosimilar Insulin Sales Price by Type (2025-2030) & (US$/Unit)
Table 151. China Biosimilar Insulin Revenue by Distribution Channel (2019-2024) & (US$ Million)
Table 152. China Biosimilar Insulin Revenue by Distribution Channel (2025-2030) & (US$ Million)
Table 153. China Biosimilar Insulin Sales by Distribution Channel (2019-2024) & (K Unit)
Table 154. China Biosimilar Insulin Sales by Distribution Channel (2025-2030) & (K Unit)
Table 155. China Biosimilar Insulin Sales Price by Distribution Channel (2019-2024) & (US$/Unit)
Table 156. China Biosimilar Insulin Sales Price by Distribution Channel (2025-2030) & (US$/Unit)
Table 157. Asia Biosimilar Insulin Revenue by Type (2019-2024) & (US$ Million)
Table 158. Asia Biosimilar Insulin Revenue by Type (2025-2030) & (US$ Million)
Table 159. Asia Biosimilar Insulin Sales by Type (2019-2024) & (K Unit)
Table 160. Asia Biosimilar Insulin Sales by Type (2025-2030) & (K Unit)
Table 161. Asia Biosimilar Insulin Sales Price by Type (2019-2024) & (US$/Unit)
Table 162. Asia Biosimilar Insulin Sales Price by Type (2025-2030) & (US$/Unit)
Table 163. Asia Biosimilar Insulin Revenue by Distribution Channel (2019-2024) & (US$ Million)
Table 164. Asia Biosimilar Insulin Revenue by Distribution Channel (2025-2030) & (US$ Million)
Table 165. Asia Biosimilar Insulin Sales by Distribution Channel (2019-2024) & (K Unit)
Table 166. Asia Biosimilar Insulin Sales by Distribution Channel (2025-2030) & (K Unit)
Table 167. Asia Biosimilar Insulin Sales Price by Distribution Channel (2019-2024) & (US$/Unit)
Table 168. Asia Biosimilar Insulin Sales Price by Distribution Channel (2025-2030) & (US$/Unit)
Table 169. Asia Biosimilar Insulin Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 170. Asia Biosimilar Insulin Revenue Grow Rate by Country (2019-2024) & (US$ Million)
Table 171. Asia Biosimilar Insulin Revenue Grow Rate by Country (2025-2030) & (US$ Million)
Table 172. Asia Biosimilar Insulin Sales by Country (2019 VS 2023 VS 2030) & (K Unit)
Table 173. Asia Biosimilar Insulin Sales by Country (2019-2024) & (K Unit)
Table 174. Asia Biosimilar Insulin Sales by Country (2025-2030) & (K Unit)
Table 175. Asia Biosimilar Insulin Sales Price by Country (2019-2024) & (US$/Unit)
Table 176. Asia Biosimilar Insulin Sales Price by Country (2025-2030) & (US$/Unit)
Table 177. Japan Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Table 178. South Korea Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Table 179. Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Table 180. Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Table 181. Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Table 182. Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Table 183. Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Table 184. Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Table 185. MEALA Biosimilar Insulin Revenue by Type (2019-2024) & (US$ Million)
Table 186. MEALA Biosimilar Insulin Revenue by Type (2025-2030) & (US$ Million)
Table 187. MEALA Biosimilar Insulin Sales by Type (2019-2024) & (K Unit)
Table 188. MEALA Biosimilar Insulin Sales by Type (2025-2030) & (K Unit)
Table 189. MEALA Biosimilar Insulin Sales Price by Type (2019-2024) & (US$/Unit)
Table 190. MEALA Biosimilar Insulin Sales Price by Type (2025-2030) & (US$/Unit)
Table 191. MEALA Biosimilar Insulin Revenue by Distribution Channel (2019-2024) & (US$ Million)
Table 192. MEALA Biosimilar Insulin Revenue by Distribution Channel (2025-2030) & (US$ Million)
Table 193. MEALA Biosimilar Insulin Sales by Distribution Channel (2019-2024) & (K Unit)
Table 194. MEALA Biosimilar Insulin Sales by Distribution Channel (2025-2030) & (K Unit)
Table 195. MEALA Biosimilar Insulin Sales Price by Distribution Channel (2019-2024) & (US$/Unit)
Table 196. MEALA Biosimilar Insulin Sales Price by Distribution Channel (2025-2030) & (US$/Unit)
Table 197. MEALA Biosimilar Insulin Revenue Grow Rate by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 198. MEALA Biosimilar Insulin Revenue Grow Rate by Country (2019-2024) & (US$ Million)
Table 199. MEALA Biosimilar Insulin Revenue Grow Rate by Country (2025-2030) & (US$ Million)
Table 200. MEALA Biosimilar Insulin Sales by Country (2019 VS 2023 VS 2030) & (K Unit)
Table 201. MEALA Biosimilar Insulin Sales by Country (2019-2024) & (K Unit)
Table 202. MEALA Biosimilar Insulin Sales by Country (2025-2030) & (K Unit)
Table 203. MEALA Biosimilar Insulin Sales Price by Country (2019-2024) & (US$/Unit)
Table 204. MEALA Biosimilar Insulin Sales Price by Country (2025-2030) & (US$/Unit)
Table 205. Mexico Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Table 206. Brazil Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Table 207. Israel Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Table 208. Argentina Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Table 209. Colombia Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Table 210. Turkey Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Table 211. Saudi Arabia Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Table 212. UAE Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Table 213. Key Raw Materials
Table 214. Raw Materials Key Suppliers
Table 215. Biosimilar Insulin Distributors List
Table 216. Biosimilar Insulin Customers List
Table 217. Research Programs/Design for This Report
Table 218. Authors List of This Report
Table 219. Secondary Sources
Table 220. Primary Sources
List of Figures
Figure 1. Biosimilar Insulin Product Picture
Figure 2. Global Biosimilar Insulin Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Biosimilar Insulin Market Size Share 2019 VS 2023 VS 2030
Figure 4. Biosimilar Insulin Glargine Picture
Figure 5. Biosimilar Insulin Lispro Picture
Figure 6. Other Picture
Figure 7. Global Biosimilar Insulin Market Size Growth Rate by Distribution Channel (US$ Million), 2019 VS 2023 VS 2030
Figure 8. Global Biosimilar Insulin Market Size Share 2019 VS 2023 VS 2030
Figure 9. Hospital Picture
Figure 10. Retail Pharmacy Picture
Figure 11. Others Picture
Figure 12. Global Biosimilar Insulin Revenue (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Biosimilar Insulin Revenue (2019-2030) & (US$ Million)
Figure 14. Global Biosimilar Insulin Revenue (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 15. Global Biosimilar Insulin Revenue Market Share by Region: 2023 Versus 2030
Figure 16. Global Biosimilar Insulin Revenue Market Share by Region (2019-2030)
Figure 17. Global Biosimilar Insulin Sales (2019-2030) & (K Unit)
Figure 18. Global Biosimilar Insulin Sales (CAGR) by Region: 2019 VS 2023 VS 2030 (K Unit)
Figure 19. Global Biosimilar Insulin Sales Market Share by Region (2019-2030)
Figure 20. US & Canada Biosimilar Insulin Sales YoY (2019-2030) & (K Unit)
Figure 21. Europe Biosimilar Insulin Sales YoY (2019-2030) & (K Unit)
Figure 22. China Biosimilar Insulin Sales YoY (2019-2030) & (K Unit)
Figure 23. Asia (Excluding China) Biosimilar Insulin Sales YoY (2019-2030) & (K Unit)
Figure 24. Middle East, Africa and Latin America (Excluding China) Biosimilar Insulin Sales YoY (2019-2030) & (K Unit)
Figure 25. Global Biosimilar Insulin Manufacturers Revenue Share Top 10 and Top 5 in 2023
Figure 26. Global Biosimilar Insulin Manufacturers Sales Share Top 10 and Top 5 in 2023
Figure 27. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 28. Global Biosimilar Insulin Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 29. Global Biosimilar Insulin Revenue Market Share by Type 2019 VS 2023 VS 2030
Figure 30. Global Biosimilar Insulin Revenue Market Share by Type (2019-2030)
Figure 31. Global Biosimilar Insulin Sales by Type (2019 VS 2023 VS 2030) & (K Unit)
Figure 32. Global Biosimilar Insulin Sales Market Share by Type 2019 VS 2023 VS 2030
Figure 33. Global Biosimilar Insulin Sales Market Share by Type (2019-2030)
Figure 34. Global Biosimilar Insulin Revenue by Distribution Channel (2019 VS 2023 VS 2030) & (US$ Million)
Figure 35. Global Biosimilar Insulin Revenue Market Share by Application 2019 VS 2023 VS 2030
Figure 36. Global Biosimilar Insulin Revenue Market Share by Distribution Channel (2019-2030)
Figure 37. Global Biosimilar Insulin Sales by Distribution Channel (2019 VS 2023 VS 2030) & (K Unit)
Figure 38. Global Biosimilar Insulin Sales Market Share by Application 2019 VS 2023 VS 2030
Figure 39. Global Biosimilar Insulin Sales Market Share by Distribution Channel (2019-2030)
Figure 40. North America Biosimilar Insulin Revenue Share by Type (2019-2030)
Figure 41. North America Biosimilar Insulin Sales Share by Type (2019-2030)
Figure 42. North America Biosimilar Insulin Revenue Share by Distribution Channel (2019-2030)
Figure 43. North America Biosimilar Insulin Sales Share by Distribution Channel (2019-2030)
Figure 44. North America Biosimilar Insulin Revenue Share by Country (2019-2030)
Figure 45. North America Biosimilar Insulin Sales Share by Country (2019-2030)
Figure 46. Europe Biosimilar Insulin Revenue Share by Type (2019-2030)
Figure 47. Europe Biosimilar Insulin Sales Share by Type (2019-2030)
Figure 48. Europe Biosimilar Insulin Revenue Share by Distribution Channel (2019-2030)
Figure 49. Europe Biosimilar Insulin Sales Share by Distribution Channel (2019-2030)
Figure 50. Europe Biosimilar Insulin Revenue Share by Country (2019-2030)
Figure 51. Europe Biosimilar Insulin Sales Share by Country (2019-2030)
Figure 52. China Biosimilar Insulin Revenue Share by Type (2019-2030)
Figure 53. China Biosimilar Insulin Sales Share by Type (2019-2030)
Figure 54. China Biosimilar Insulin Revenue Share by Distribution Channel (2019-2030)
Figure 55. China Biosimilar Insulin Sales Share by Distribution Channel (2019-2030)
Figure 56. Asia Biosimilar Insulin Revenue Share by Type (2019-2030)
Figure 57. Asia Biosimilar Insulin Sales Share by Type (2019-2030)
Figure 58. Asia Biosimilar Insulin Revenue Share by Distribution Channel (2019-2030)
Figure 59. Asia Biosimilar Insulin Sales Share by Distribution Channel (2019-2030)
Figure 60. Asia Biosimilar Insulin Revenue Share by Country (2019-2030)
Figure 61. Asia Biosimilar Insulin Sales Share by Country (2019-2030)
Figure 62. MEALA Biosimilar Insulin Revenue Share by Type (2019-2030)
Figure 63. MEALA Biosimilar Insulin Sales Share by Type (2019-2030)
Figure 64. MEALA Biosimilar Insulin Revenue Share by Distribution Channel (2019-2030)
Figure 65. MEALA Biosimilar Insulin Sales Share by Distribution Channel (2019-2030)
Figure 66. MEALA Biosimilar Insulin Revenue Share by Country (2019-2030)
Figure 67. MEALA Biosimilar Insulin Sales Share by Country (2019-2030)
Figure 68. Biosimilar Insulin Value Chain
Figure 69. Manufacturing Cost Structure
Figure 70. Biosimilar Insulin Production Mode & Process
Figure 71. Direct Comparison with Distribution Share
Figure 72. Distributors Profiles
Figure 73. Years Considered
Figure 74. Research Process
Figure 75. Key Executives Interviewed
